Alfredo Tartarone1, Giandomenico Roviello2, Rosa Lerose3, Raheleh Roudi4, Michele Aieta1, Pietro Zoppoli5. 1. Unit of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB Referral Cancer Center of Basilicata Rionero in Vulture (PZ), Italy. 2. Department of Health Sciences, University of Florence, viale Pieraccini, 6, 50139, Florence, Italy. 3. Hospital Pharmacy, IRCCS-CROB Referral Cancer Center of Basilicata Rionero in Vulture (PZ), Italy. 4. Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran. 5. Laboratory of Preclinical & Translational Research, IRCCS-CROB Referral Cancer Center of Basilicata Rionero in Vulture (PZ), via Padre Pio 1, 85028, Italy.
Abstract
Aim: At present three immune checkpoint inhibitors (ICIs), two anti-PD-1 (nivolumab and pembrolizumab) and one anti-PD-L1 (atezolizumab) can be used in pretreated non-small-cell lung cancer patients. The aim of this meta-analysis is an indirect comparison between anti-PD-1 and anti-PD-L1 inhibitors. Methods: Seven studies (>4000 patients) were considered. Results: Considering the overall survival ICIs showed very robust efficacy over docetaxel, while in terms of progression-free survival the therapy with ICIs is slightly favored. Anti-PD-1 gives a more significant benefit than anti-PD-L1; however, excluding the KEYNOTE 010 trial that enrolled only PD-L1-positive patients, the subgroup difference remains only in terms of progression-free survival. Conclusion: This meta-analysis confirms the superiority of ICIs over docetaxel in pretreated non-small-cell lung cancer patients and would indicate a slight benefit from anti-PD-1 than from anti-PD-L1 inhibitors, always keeping in mind the possible biases of this indirect comparison.
Aim: At present three immune checkpoint inhibitors (ICIs), two anti-PD-1 (nivolumab and pembrolizumab) and one anti-PD-L1 (atezolizumab) can be used in pretreated non-small-cell lung cancerpatients. The aim of this meta-analysis is an indirect comparison between anti-PD-1 and anti-PD-L1 inhibitors. Methods: Seven studies (>4000 patients) were considered. Results: Considering the overall survival ICIs showed very robust efficacy over docetaxel, while in terms of progression-free survival the therapy with ICIs is slightly favored. Anti-PD-1 gives a more significant benefit than anti-PD-L1; however, excluding the KEYNOTE 010 trial that enrolled only PD-L1-positive patients, the subgroup difference remains only in terms of progression-free survival. Conclusion: This meta-analysis confirms the superiority of ICIs over docetaxel in pretreated non-small-cell lung cancerpatients and would indicate a slight benefit from anti-PD-1 than from anti-PD-L1 inhibitors, always keeping in mind the possible biases of this indirect comparison.
Authors: Yutao Li; Amit Sharma; Xiaolong Wu; Hans Weiher; Dirk Skowasch; Markus Essler; Ingo G H Schmidt-Wolf Journal: Front Oncol Date: 2022-05-11 Impact factor: 5.738